629 Expression of Apoptosis-Regulating Genes in the Rat Prostate After Bont/a Injection

The injection of Botulinum toxin type A (BoNT/A) into the prostate is a minimally invasive alternative treatment for lower urinary tract symptoms. To summarize the action mechanisms of BoNT/A on experimental animals and to analyze its effectiveness according to published clinical studies, we located 24 papers on the treatment of HBP with BoNT/A. The doses applied ranged from 100 (OnabotA) to 600 U (OnabotA and AbobotA). The IPSS score presented a mean post-treatment reduction, for all series, of 10.8 + 2.66 points. Other significant results included the overall mean reduction in QoL score of 2.1 ± 0.62 points, and the pre and post-treatment differences in prostate volume (22.43 ± 20.2 cm(3)), post-voiding residue (76.77 + 51.72 cm(3)) and PSA (1.15 + 0.93 ng/ml). However, only two clinical trials were on sufficient quality to be selected for meta-analysis, and it was observed that the difference of the means, pre- and post-treatment of maximum flow, prostate volume, IPSS and PSA were not statistically significant (P = 0.18). Neither was there any statistically significant difference between pre- and post-treatment post-voiding residue (P = 0.65). In conclusion, BoNT/A alleviates lower urinary tract symptoms due to HBP, but different studies present considerable variations regarding the dose administered, inclusion criteria and follow-up time, as well as poorly defined retreatment, losses to follow up and, above all, a high degree of variability in the communication of results (with large standard deviations). In consequence, further clinical trials are needed.

show abstract

“…We located nine studies on BTX treatment on rats7, 11, 27–33 and two with dogs 7, 11. The doses used were 51,020 U in rats and 100,200 U in dogs.…”

Section: Methodsmentioning

confidence: 99%

“…The patients' mean prostate volume (PV), in the various series, ranged from 19.6 ± 224 to 75.1 cm 3 33 and 106 cm 3 39. Chuang et al23 and Nikoobakht et al20 were the only authors to stratify the patients' baseline parameters by PV greater or less than 30 cm 3 (see Table II).…”

Section: Methodsmentioning

confidence: 99%

The use of botulinum toxin in benign prostatic hyperplasia

Pérez

Herrera

et al. 2011

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

629 Expression of Apoptosis-Regulating Genes in the Rat Prostate After Bont/a Injection

Cited by 1 publication

References 0 publications

The use of botulinum toxin in benign prostatic hyperplasia

The use of botulinum toxin in benign prostatic hyperplasia

Contact Info

Product

Resources

About